MEDIVIR AB – INTERIM REPORT, THIRD QUARTER 2015
Financial summary Third quarter 2015 (2014) · Net turnover totalled SEK 111.5 million (617.8 m), of which SEK 69.0 million (516.4 m) comprised royalties for simeprevir, where of SEK 11.5 million referred to past periods. · Revenues from Medivir’s own pharmaceutical sales totalled SEK 42.6 million (100.8 m), of which SEK 2.8 million (61.6 m) derived from sales of OLYSIO® and SEK 39.8 million (39.2 m) from sales of other pharmaceuticals. · The loss after tax was SEK -10.5 million (373.7 m). · Basic and diluted earnings per share totalled SEK -0.36 (11.95) and SEK -0.